Shari Damast
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shari Damast has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
Jeanne Carter
Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York
3 shared publications- Jessie Y. Li
Yale University School of Medicine, New Haven, CT, USA
3 shared publications - Melissa Rasar Young
Department of Therapeutic Radiology, Yale School of Medicine , New Haven, CT
3 shared publications - Alessandro Davide Santin
Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA
2 shared publications Anne Eaton
Memorial Sloan-Kettering Cancer Center
2 shared publicationsElena Ratner
Yale Univ, Dept Obstet & Gynecol, Sch Med, New Haven, CT USA
2 shared publications
Latest Publications
- 7 March 2022
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 32 (3) , 323-331
Radiation therapy in the definitive management of medically inoperable endometrial cancer
The incidence of endometrial cancer continues to increase worldwide with growing life expectancy and rates of obesity. While endometrial cancer is primarily a surgical disease managed with hysterectomy, a small proportion of patients are deemed to be poor surgical candidates due to their co-morbidities. These medically inoperable patients should be considered for curative treatment with definitive radiation therapy, and brachytherapy is an integral component of their care. Referral to a high-volume center early on in the care of potentially inoperable patients is crucial to optimize their management. These patients should be evaluated by a high-risk surgical and anesthesia team to confirm their medical inoperability. For inoperable patients, use of image-guided brachytherapy is encouraged. Brachytherapy applicator selection is determined based on a patient’s anatomy, uterine size, and extent of tumor. Advances in anatomic and functional imaging including multiparametric magnetic resonance imaging (MRI) have improved clinical staging of these patients and have also allowed for the delivery of three-dimensional image-guided brachytherapy with improved accuracy. With recent consensus guidelines to guide local computed tomography and/or MRI volume-based delineation of targets and organs-at-risk, local outcomes have improved and treatments are delivered with less acute and late morbidity. Ongoing trials are looking at novel systemic agents, such as immunotherapy, to induce a systemic anti-tumor immune response and improve outcomes in these patients.
- 7 March 2022
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 32 (3) , 323-331
Radiation therapy in the definitive management of medically inoperable endometrial cancer
The incidence of endometrial cancer continues to increase worldwide with growing life expectancy and rates of obesity. While endometrial cancer is primarily a surgical disease managed with hysterectomy, a small proportion of patients are deemed to be poor surgical candidates due to their co-morbidities. These medically inoperable patients should be considered for curative treatment with definitive radiation therapy, and brachytherapy is an integral component of their care. Referral to a high-volume center early on in the care of potentially inoperable patients is crucial to optimize their management. These patients should be evaluated by a high-risk surgical and anesthesia team to confirm their medical inoperability. For inoperable patients, use of image-guided brachytherapy is encouraged. Brachytherapy applicator selection is determined based on a patient’s anatomy, uterine size, and extent of tumor. Advances in anatomic and functional imaging including multiparametric magnetic resonance imaging (MRI) have improved clinical staging of these patients and have also allowed for the delivery of three-dimensional image-guided brachytherapy with improved accuracy. With recent consensus guidelines to guide local computed tomography and/or MRI volume-based delineation of targets and organs-at-risk, local outcomes have improved and treatments are delivered with less acute and late morbidity. Ongoing trials are looking at novel systemic agents, such as immunotherapy, to induce a systemic anti-tumor immune response and improve outcomes in these patients.
- Open Access
- 1 January 2022
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 14 (1) , 66-71
Single application hybrid interstitial brachytherapy for cervical cancer: An institutional approach during the COVID-19 pandemic
Introduction To ease anesthesia and inpatient strain during the COVID-19 pandemic, our institution’s policy for hybrid intracavitary-interstitial brachytherapy (IC/ISBT) for cervical cancer (CC) was modified from multiple applications (MA) treated over 2 separate weeks (7 Gy × 4) to a...
- 1 January 2022
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 14 (1) , 66-71
Open AccessSingle application hybrid interstitial brachytherapy for cervical cancer: An institutional approach during the COVID-19 pandemic
Introduction To ease anesthesia and inpatient strain during the COVID-19 pandemic, our institution’s policy for hybrid intracavitary-interstitial brachytherapy (IC/ISBT) for cervical cancer (CC) was modified from multiple applications (MA) treated over 2 separate weeks (7 Gy × 4) to a...
- Open Access
- 1 January 2022
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 33 (2) , e13
An evaluation of prognostic factors, oncologic outcomes, and management for primary and recurrent squamous cell carcinoma of the vulva
Li JY, et al. J Gynecol Oncol. 2021 Nov;33:e13. https://doi.org/10.3802/jgo.2022.33.e13
- 1 January 2022
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 33 (2) , e13
Open AccessAn evaluation of prognostic factors, oncologic outcomes, and management for primary and recurrent squamous cell carcinoma of the vulva
Li JY, et al. J Gynecol Oncol. 2021 Nov;33:e13. https://doi.org/10.3802/jgo.2022.33.e13
- 1 December 2021
- Published by Elsevier in Gynecologic Oncology
- Vol. 163 (3) , 557-562
Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy
- 1 December 2021
- Published by Elsevier in Gynecologic Oncology
- Vol. 163 (3) , 557-562
Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy
- 1 November 2021
- Published by Elsevier in Practical Radiation Oncology
- Vol. 11 (6) , 448-452
Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer
- 1 November 2021
- Published by Elsevier in Practical Radiation Oncology
- Vol. 11 (6) , 448-452
Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer
- 1 November 2020
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 152, S1098-S1099
OC-1048: Use of Ultrasound-Compatible Models for Simulation-Based Gynecological Education
- 1 November 2020
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 152, S1098-S1099
OC-1048: Use of Ultrasound-Compatible Models for Simulation-Based Gynecological Education
- Open Access
- 1 January 2020
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 31 (4)
Stage III uterine serous carcinoma: modern trends in multimodality treatment
Li JY, et al. J Gynecol Oncol. 2019 Jun;31:e53. https://doi.org/10.3802/jgo.2020.31.e53
- 1 January 2020
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 31 (4)
Open AccessStage III uterine serous carcinoma: modern trends in multimodality treatment
Li JY, et al. J Gynecol Oncol. 2019 Jun;31:e53. https://doi.org/10.3802/jgo.2020.31.e53
- 1 January 2020
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 30 (1) , 48-55
Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy
Introduction Risk factors for pelvic recurrence in early stage endometrial cancer are poorly understood. We sought to describe outcomes, patterns of failure, and risk factors for recurrence among patients with grade 2–3 endometrial cancer with deep myometrial invasion who were treated with vaginal brachytherapy as sole adjuvant therapy after hysterectomy and lymph node dissection. Methods We retrospectively reviewed the records of stage I patients with grade 2–3 endometrioid histology and ≥50% myometrial invasion treated at an academic institution from January 2005 to December 2017. Only patients with endometrioid histology were included. Mixed histologies, including papillary serous or clear cell components, were excluded. Further exclusion criteria were International Federation of Gynecology and Obstetrics stage IB grade 1 patients, follow-up time less than 3 months, receipt of pelvic irradiation or any form of systemic therapy (chemotherapy, aromatase inhibitor). Overall survival, disease-free survival, and pelvic recurrence-free survival were calculated with Kaplan–Meier methods. Multivariable Cox proportional hazards regression was used to analyze factors associated with overall survival and disease-free survival. Results Among 131 consecutive patients identified, 111 (85%) patients met the inclusion criteria. The majority (98.2%) underwent lymph node dissection with ≥10 lymph nodes removed in 78.9%. With a median follow-up of 36 months (IQR 12–70 months), the 3-year overall survival, disease-free survival, and pelvic recurrence-free survival were 89.6%, 90.1%, and 92.8%, respectively. Histologic grade 3, older age, and lymphovascular invasion were not associated with inferior outcomes; however, lower uterine segment involvement (p=0.031), tumor size >4 cm (p=0.024), and Conclusion Among patients with stage IB grade 2–3 endometrial cancer treated with vaginal brachytherapy, the risk factors for recurrence (larger tumor size and lower uterine segment involvement) in conjunction with established risk factors (high grade, ≥50% myometrial invasion, and lymphovascular invasion) may identify a group of high-risk patients who might benefit from pelvic radiotherapy.
- 1 January 2020
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 30 (1) , 48-55
Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy
Introduction Risk factors for pelvic recurrence in early stage endometrial cancer are poorly understood. We sought to describe outcomes, patterns of failure, and risk factors for recurrence among patients with grade 2–3 endometrial cancer with deep myometrial invasion who were treated with vaginal brachytherapy as sole adjuvant therapy after hysterectomy and lymph node dissection. Methods We retrospectively reviewed the records of stage I patients with grade 2–3 endometrioid histology and ≥50% myometrial invasion treated at an academic institution from January 2005 to December 2017. Only patients with endometrioid histology were included. Mixed histologies, including papillary serous or clear cell components, were excluded. Further exclusion criteria were International Federation of Gynecology and Obstetrics stage IB grade 1 patients, follow-up time less than 3 months, receipt of pelvic irradiation or any form of systemic therapy (chemotherapy, aromatase inhibitor). Overall survival, disease-free survival, and pelvic recurrence-free survival were calculated with Kaplan–Meier methods. Multivariable Cox proportional hazards regression was used to analyze factors associated with overall survival and disease-free survival. Results Among 131 consecutive patients identified, 111 (85%) patients met the inclusion criteria. The majority (98.2%) underwent lymph node dissection with ≥10 lymph nodes removed in 78.9%. With a median follow-up of 36 months (IQR 12–70 months), the 3-year overall survival, disease-free survival, and pelvic recurrence-free survival were 89.6%, 90.1%, and 92.8%, respectively. Histologic grade 3, older age, and lymphovascular invasion were not associated with inferior outcomes; however, lower uterine segment involvement (p=0.031), tumor size >4 cm (p=0.024), and Conclusion Among patients with stage IB grade 2–3 endometrial cancer treated with vaginal brachytherapy, the risk factors for recurrence (larger tumor size and lower uterine segment involvement) in conjunction with established risk factors (high grade, ≥50% myometrial invasion, and lymphovascular invasion) may identify a group of high-risk patients who might benefit from pelvic radiotherapy.
- 1 November 2019
- Published by Elsevier in Practical Radiation Oncology
- Vol. 9 (6) , 479-491
Literature Review of Vaginal Stenosis and Dilator Use in Radiation Oncology
- 1 November 2019
- Published by Elsevier in Practical Radiation Oncology
- Vol. 9 (6) , 479-491
Literature Review of Vaginal Stenosis and Dilator Use in Radiation Oncology
- Open Access
- 1 January 2017
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 28 (6) , e84
Impact of vaginal cylinder diameter on outcomes following brachytherapy for early stage endometrial cancer
Qian JM, et al. J Gynecol Oncol. 2017 Jul;28(6):e84. https://doi.org/10.3802/jgo.2017.28.e84
- 1 January 2017
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 28 (6) , e84
Open AccessImpact of vaginal cylinder diameter on outcomes following brachytherapy for early stage endometrial cancer
Qian JM, et al. J Gynecol Oncol. 2017 Jul;28(6):e84. https://doi.org/10.3802/jgo.2017.28.e84